Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan

PharmacoEconomics

Volumn 27, Issue 3, 2009, Pages 247-261

  Igarashi, Ataru ^a   Takuma, Hiroki ^b   Fukuda, Takashi ^c   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST UTILITY ANALYSIS; COUNSELING; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; JAPAN; MALE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SMOKING CESSATION; UNIVARIATE ANALYSIS;

ADULT; AGED; BENZAZEPINES; COMBINED MODALITY THERAPY; COUNSELING; FEMALE; HUMANS; JAPAN; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUINOXALINES; RECURRENCE; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 64749086006     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927030-00007     Document Type: Article

References (57)

1. Ministry of Health, Labour, and Welfare. National health and nutrition examination survey 2005 [in Japanese]. Tokyo: Ministry of Health, Labour, and Welfare, 2005 [online]. Available from URL: http://www.mhlw.go.jp/houdou/2005/ 04/h0421-1b.html [Accessed 2007 Jul. 1]
2. Organisation for Economic Cooperation and Development (OECD). OECD health data 2007: statistics and indicators for 30 countries on CD-ROM. Paris: OECD, 2007
3. Tsutani K, Kataoka T, Ogata E, et al. Uninsured medicines in Japan as of 2002 [in Japanese]. Jpn J Clin Pharmacol Ther 2003; 34(1): 161-2
4. Japan Health Promotion Fitness Foundation. National health promotion in the 21st century (Healthy Japan 21) [in Japanese; online]. Available from URL: http://www.kenkounip-pon21.gr.jp/kenkounippon21/about/intro/index-menul.html [Accessed. 2008 Apr 18]
5. Health Promotion Law (Act no. 103; 2002) [in Japanese; online]. Available from URL: http://law.e-gov.go.jp/htmldata/H14/H14HO103.html [Accessed 2008 Sep 18]
6. The Ministry of Foreign Affaire of Japan. The framework, convention on tobacco control; 2003 [in Japanese; online]. Available from URL: http://www.mofa.go.jp/mofaj/gaiko/treaty/pdfs/treaty159-17a.pdf [Accessed 2008 Sep 18]
7. Institute of Social Insurance. National tariff of medical fees 2006 [in Japanese]. Tokyo: Institute of Social Insurance, 2006
8. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005 May 19; 48 (10): 3474-7
9. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007 Mar; 52 (3): 985-94
10. Jackson 2nd KC, Nahoopii R, Said Q, et al. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med 2007 Apr; 49 (4): 453-60
11. Halpern M, Dirani R, Schmier J. Impacts of a smoking cessation benefit among employed populations. J Occup Environ Med 2007 Jan; 49(1): 11-2.1
12. National Institute for Health and Clinical Excellence (NICE). Varenicline for smoking cessation. London: NICE, 2007:1-12 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA123Guidance.pdf [Accessed 2007 Jul 1]
13. Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008; 26 (6): 497-511
14. Parrot S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation intervention. Thorax 1998; 53 Suppl. 5: S1-S37
15. Godfrey C, Parrott S, Coleman T, et al. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005 Apr; 100 Suppl. 2: 70-83
16. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997 Dec 3; 278 (21): 1759-66
17. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999 Jul 17; 354 (9174): 210-5
18. Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol. Assess 2002; 6 (16): 1-245
19. Orme ME, Hogue SL, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001 Mar; 10 (1): 55-61
20. Bolin K, Lindgren B, Willers S, et al. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest 2006 Mar; 129 (3): 65.1-60
21. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et. al. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8 (3): 178-90
22. Hoogenveen RT, Gijsen R, Van Genugten MLL, et al. Constructing a set of consistent data for chronic disease modeling. Bilthoven: National Institute of Public Health and the Environment (RIVM), 2000
23. Takuma H, Igarashi A, Fukuda T, et al. Literature search of economic evaluations of smoking cessation therapy [abstract; in Japanese]. 126th Annual Meeting of the Pharmaceutical Society of Japan; 2006 Mar 29; Sendai: 190
24. Kawata C, Tamura M. Research on economic effects of health promotion activities (anti-tobacco). In: FY1995 Annual Report of Grants for Scientific Research by the Ministry of Health of Japan [in Japanese], Tokyo: Japan Wellness Foundation, 1996: 32-52
25. Nakamura M, Tamura M, Seki Y, et al. Economic evaluation of smoking cessation programs [in Japanese]. J Japanese Soc Health Educ Health Promot 1.998; 6 Suppl.: 152-3
26. Nakamura M. International comparison research on anti-tobacco policy. In: FY1995 Annual Report of Grants for Scientific Research by the Ministry of Health of Japan [in Japanese]. Tokyo: Japan Wellness Foundation, 1996: 6-28
27. Tamura M, Nakamura M, Masui S, et al. Cost-effectiveness analysis of smoking cessation programs [in Japanese], Japanese J Public Health 2001; 48 Suppl.: 240
28. Nakamura M, Miura M, Oshima A, et al. The development of health risk appraisal for Japanese as a new health educational tool [in Japanese]. Gan No Rinsho 1989 Jan; 35 (2): 177-81
29. Hirayama T. A large scale cohort study on the effect of life styles on the risk of cancer by each site [in Japanese]. Gan No Rinsho 1990 Feb; Spec No: 233-42
30. Shibuya K, Ciecierski. C, Guindon E, et al. WHO Framework Convention on Tobacco Control: development of an evidence based global health treaty. BMJ 2003 Jul 19; 327 (7407): 154-7
31. Levy DT, Friend K. Examining the effects of tobacco treatment policies on smoking rates and smoking related deaths using the SimSmoke computer simulation model. Tob Control 2002 Mar; 11(1): 47-54
32. Ministry of Health, Labour, and Welfare. Abridged life table 2004. Tokyo: Ministry of Health, Labour, and Welfare, 2005 [online]. Available from URL: http://www.mhlw,go.jp/toukei/ saikin/hw/life/life 04/ [Accessed 2007 Jul 1]
33. Inoue M, Hanaoka T, Sasazuki S, et al. Impact of tobacco smoking on subsequent cancer risk among middle-aged Japanese men and women: data from a large-scale population-based cohort study in Japan. The JPHC study. Prev Med 2004 May; 38 (5): 516-22
34. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebocontrolled dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007 Jun; 29 (6): 1040-56
35. Ministry of Health, Labour, and Welfare. Patient survey 2002 [in Japanese]. Tokyo: Ministry of Health, Labour, and Welfare, 2002 [online]. Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/kanja/02/index.html [Accessed 2007 Jul 1]
36. Ministry of Health, Labour, and Welfare. Survey of medical care activities in public health insurance 2002. Tokyo: Ministry of Health, Labour, and Welfare, 2002 [online]. Available from URL: http://www.mhlw.go.jp/toukei/ saikin/hw/sinryo/tyosa02/index.html [Accessed 2007 Jul 1]
37. Ministry of Health, Labor and Welfare. Notification no. 285. Official Gazette 2008 Apr 18:4
38. Ministry of Health, Labour, and Welfare. Survey of medical care activities in public health insurance 2005 [in Japanese]. Tokyo: Ministry of Health, Labour, and Welfare, 2005 [on line]. Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/sinryo/tyosa 05/index.html [Accessed 2007 Oct 15]
39. Tsukuma H, Ajiki W, Oshima A. Cancer incidence rates in Japan and their transition. In: Oshima A, Kuroishi T, Tajima K, editors. The white paper of cancer statistics 2004 [in Japanese]. Tokyo: Shinohara Shuppan Shinsha, 2004: 97-160
40. Japan Arteriosclerosis Longitudinal Study (JALS) Group. Japan Arteriosclerosis Longitudinal Study: existing cohorts combine (JALS-ECC). Rational, design, and population characteristics. Circ J 2008; 72 (10): 1563-8
41. Oshima A, Tsukuma H, Ajiki W, et al. Estimation of survival rate for cancer patients diagnosed in 1993 (interim report) in Japan. In: Oshima A, Kuroishi T, Tajima K, editors. The white paper of cancer statistics 2004 [in Japanese]. Tokyo: Shinohara Shuppan Shinsha, 2004: 161-9
42. Vital statistics of demography of Japan 1999 [in Japanese]. Tokyo: Ministry of Health, 1999
43. Ministry of Health. Survey of smoking habits and health status 1998 [in Japanese]. Tokyo: Ministry of Health, 1998 [online]. Available from URL: http://www.mhlw.go.Jp/houdou/1111/h11 11-2-11.html [Accessed 2007 Jul 1]
44. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000 Jun; 38 (6): 583-637
45. Osaka Medical Centre for Health Science and Promotion. The fact-finding survey for nicotine dependence and smoking cessation behavior [in Japanese]. Osaka: Osaka Medical Centre for Health Science and Promotion, 2005
46. Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004 Dec; 39 (6): 1156-63
47. Ikeda S, Ikegami N, the Japanese EuroQol Tariff Project. Health status in Japanese population: results from Japanese EuroQol study. J Health Care Soc 1999; 9 (3): 83-91
48. Sobue T, Yamamoto S, Hara M, JPHC Study Group. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer 2002; 99 (2): 245-51
49. Sasazuki S, Sasaki S, Tsugane S, JPHC Study Group. Cigarette smoking, alcohol consumption and subsequent gastric cancer risk by subsite and histologic type. Int J Cancer 2002; 101 (6): 560-6
50. Otani T, Isasaki M, Yamamoto S, et al. Alcohol consumption, smoking and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan, public health center-based prospective study. Cancer Epidemiol Biomarkers Prev 2003; 12: 1492-500
51. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004: 33 [online]. Available from URL: http://www.nice.org.uk/nice Media/pdf/TAP-Methods.pdf [Accessed 2007 Jul 1]
52. Okusa Y, Sugawara T. Research on maximum willingness-to-pay for additional 1 QALY in Japan [in Japanese]. J Health Care Soc 2006; 16(2): 157-65
53. Ministry of Health, Labour, and Welfare. Vital statistics of demography of Japan 2003 [in Japanese]. Tokyo: Ministry of Health, Labour, and Welfare, 2003 [online]. Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/ jinkou/geppo/nengai03/index.html [Accessed 2007 Jul 1]
54. Sloan FA, Ostermann J, Picone G, et al. The price of smoking. London: The MIT Press, 2004: 1-313
55. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
56. Kojima S, Sakakibara H, Motani S, et al. Incidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese population. J Epidemiol 2007 Mar; 17 (2): 54-60
57. Institute for Health Economics and Policy in Japan. Research report of cost-benefit analysis of smoking cessation policy [in Japanese]. Institute for Health Economics and Policy in Japan, 1998:62-106